stockportfolio.pro
argenx SE (ARGX)
Healthcare · Biotechnology · NasdaqGS
argenx SE revenue & earnings — last 4 fiscal years
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $410.75M | $1.23B | $2.19B | $4.15B |
| Gross profit | $381.31M | $1.11B | $1.96B | $3.70B |
| Net income | $-709.59M | $-295.05M | $833.04M | $1.29B |
| Net margin | -172.8% | -24.1% | 38.0% | 31.1% |
Source: argenx SE SEC filings (10-K).
What growth is priced into ARGX stock?
At today's market cap of $55.71B, argenx SE is priced for free-cash-flow growth of about 29.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $573.51M from the FY ending 2025-12-31). This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 4 years of argenx SE financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ARGX in your portfolio →
argenx SE financial history by metric
About argenx SE
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
argenx SE — frequently asked questions
What is argenx SE's revenue?
argenx SE (ARGX) reported revenue of $4.15B for fiscal year 2025, up 89.6% from the prior year, according to its SEC filings.
Is argenx SE profitable?
Yes. ARGX earned net income of $1.29B in fiscal 2025, a net margin of 31.1%.
What is ARGX's P/E ratio?
argenx SE trades at a price-to-earnings ratio of about 39.6 based on the latest data in our nightly-refreshed cache.
How fast is argenx SE growing?
ARGX's revenue grew at roughly 116.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does argenx SE have?
As of fiscal year 2025, ARGX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is argenx SE's gross margin?
ARGX's gross margin was 89.1% in fiscal 2025 — gross profit of $3.70B on revenue of $4.15B.
What is argenx SE's market cap?
argenx SE (ARGX) has a market capitalization of about $55.71B, based on the latest data in our nightly-refreshed cache.
When does argenx SE's fiscal year end?
ARGX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into ARGX stock?
At today's market cap of $55.71B, argenx SE is priced for free-cash-flow growth of about 29.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $573.51M from the FY ending 2025-12-31).
Where does this data come from?
All figures are computed from argenx SE's official SEC filings (10-K and 10-Q), covering 4 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.